You are here:

  1. Home
  2. NICE Guidance
  3. NICE Advice
  4. Evidence summaries

Minimal change disease and focal segmental glomerulosclerosis in adults: rituximab

  • Evidence summary
  • Reference number: ES1
  • Published:  04 November 2016
  • Advice
  • Information for the public
Download (PDF)
  • About this information
  • Licensing medicines
  • What are minimal change disease and focal segmental glomerulosclerosis?
  • About rituximab
  • Summary of possible benefits and harms
  • Prescribing rituximab
  • More information

More information

NICE has published information about how evidence summaries for unlicensed and off-label medicines are developed.

ISBN: 978-1-4731-2149-2

This page was last updated: 04 November 2016


Previous page Prescribing rituximab
Back to top